...
首页> 外文期刊>Diagnostic pathology >Next generation sequencing to decipher concurrent loss of PMS2 and MSH6 in colorectal cancer
【24h】

Next generation sequencing to decipher concurrent loss of PMS2 and MSH6 in colorectal cancer

机译:下一代测序以解复分别损失PMS2和MSH6在结肠直肠癌中

获取原文
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND:Immunohistochemistry (IHQ) is commonly used for the detection of mismatch repair proteins deficiency (MMRD). One very infrequent abnormal pattern of MMR protein expression is the loss of PMS2 and MSH6, with intact expression of MLH1 and MSH2.CASE PRESENTATION:We review the frequency of this MMRD IHC pattern among 108 colorectal (CRCs) and 35 endometrial cancers in our files with loss of expression of at least one protein, and present two CRCs showing loss of PMS2 and MSH6 protein expression (1.9% of CRCs). NGS analysis of these tumours identified PMS2 mutations (R134* germline mutation in one tumour and M1R and c.1239delA somatic mutation in the other) as the primary event and somatic MSH6 mutation (c.3261dupC) as the secondary event in both tumours.CONCLUSIONS:This study suggests that Next Generation Sequencing (NGS) tumour analysis should be considered in the algorithm of Lynch syndrome screening to detect MMR gen somatic mutation in inconclusive cases.
机译:背景:免疫组织化学(IHQ)通常用于检测不匹配修复蛋白缺乏(MMRD)。 MMR蛋白表达的一个非常罕见的异常模式是PMS2和MSH6的损失,具有MLH1和MSH2.CASE呈现的完整表达:我们在我们的文件中审查了108名结肠直肠(CRC)和35个子宫内膜癌中这种MMRD IHC模式的频率随着至少一种蛋白质的表达丧失,并且存在两种CRC,显示出PMS2和MSH6蛋白表达(1.9%CRC)的损失。 NGS分析这些肿瘤的分析鉴定了PMS2突变(在一个肿瘤中的R134 *种系突变,另一个肿瘤和C.1239dela体细胞突变,另一个)作为初级事件和体细胞MSH6突变(C.3261Dupc)作为肿瘤中的次要事件.Conclusions [本研究表明,应在林奇综合征筛查算法中考虑下一代测序(NGS)肿瘤分析,以检测不确定病例的MMR Gen躯体突变。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号